Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07192211
PHASE2
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
Sponsor: Rohto Pharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.
Official title: Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo Coronary Artery Bypass Surgery
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-09
Completion Date
2029-03-31
Last Updated
2025-09-25
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
Mesenchymal stem cell
ADR-002K administration
BIOLOGICAL
Placebo
Placebo